Commonwealth Equity Services’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $237K | Buy |
1,185
+80
| +7% | +$15.8K | ﹤0.01% | 3844 |
|
|
2025
Q4 | $209K | Buy |
+1,105
| New | +$212K | ﹤0.01% | 3951 |
|
|
2022
Q1 | – | Sell |
-10,176
| Closed | -$980K | – | 3762 |
|
|
2021
Q4 | $980K | Buy |
10,176
+7,704
| +312% | +$712K | ﹤0.01% | 2003 |
|
|
2021
Q3 | $214K | Hold |
2,472
| – | – | ﹤0.01% | 3220 |
|
|
2021
Q2 | $202K | Sell |
2,472
-46
| -2% | -$3.83K | ﹤0.01% | 3256 |
|
|
2021
Q1 | $239K | Buy |
+2,518
| New | +$238K | ﹤0.01% | 2979 |
|
|
2020
Q4 | – | Sell |
-3,924
| Closed | -$233K | – | 3237 |
|
|
2020
Q3 | $233K | Buy |
3,924
+133
| +4% | +$9.07K | ﹤0.01% | 2581 |
|
|
2020
Q2 | $264K | Buy |
+3,791
| New | +$240K | ﹤0.01% | 2373 |
|
|
2020
Q1 | – | Sell |
-3,350
| Closed | -$217K | – | 2902 |
|
|
2019
Q4 | $217K | Sell |
3,350
-826
| -20% | -$55.2K | ﹤0.01% | 2556 |
|
|
2019
Q3 | $259K | Sell |
4,176
-3,857
| -48% | -$242K | ﹤0.01% | 2363 |
|
|
2019
Q2 | $572K | Buy |
8,033
+1,866
| +30% | +$137K | ﹤0.01% | 1703 |
|
|
2019
Q1 | $483K | Buy |
+6,167
| New | +$467K | ﹤0.01% | 1782 |
|
|
2018
Q4 | – | Sell |
-2,558
| Closed | -$438K | – | 2765 |
|
|
2018
Q3 | $438K | Buy |
2,558
+878
| +52% | +$132K | ﹤0.01% | 1875 |
|
|
2018
Q2 | $217K | Sell |
1,680
-258
| -13% | -$28.8K | ﹤0.01% | 2392 |
|
|
2018
Q1 | $199K | Sell |
1,938
-462
| -19% | -$45.7K | ﹤0.01% | 2413 |
|
|
2017
Q4 | $205K | Sell |
2,400
-258
| -10% | -$22.4K | ﹤0.01% | 2351 |
|
|
2017
Q3 | $226K | Hold |
2,658
| – | – | ﹤0.01% | 2185 |
|
|
2017
Q2 | $201K | Buy |
+2,658
| New | +$186K | ﹤0.01% | 2229 |
|
|
2017
Q1 | – | Sell |
-7,502
| Closed | -$476K | – | 2449 |
|
|
2016
Q4 | $476K | Buy |
7,502
+1,529
| +26% | +$96.5K | ﹤0.01% | 1433 |
|
|
2016
Q3 | $380K | Sell |
5,973
-872
| -13% | -$64K | ﹤0.01% | 1551 |
|
|
2016
Q2 | $509K | Sell |
6,845
-2,787
| -29% | -$207K | ﹤0.01% | 1347 |
|
|
2016
Q1 | $644K | Sell |
9,632
-106
| -1% | -$6.44K | 0.01% | 1178 |
|
|
2015
Q4 | $659K | Buy |
9,738
+3,239
| +50% | +$200K | 0.01% | 1140 |
|
|
2015
Q3 | $347K | Buy |
6,499
+3,247
| +100% | +$197K | ﹤0.01% | 1467 |
|
|
2015
Q2 | $205K | Sell |
3,252
-2,301
| -41% | -$126K | ﹤0.01% | 1909 |
|
|
2015
Q1 | $267K | Sell |
5,553
-4,679
| -46% | -$179K | ﹤0.01% | 1714 |
|
|
2014
Q4 | $340K | Sell |
10,232
-321
| -3% | -$10.4K | ﹤0.01% | 1485 |
|
|
2014
Q3 | $309K | Buy |
+10,553
| New | +$350K | ﹤0.01% | 1532 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Commonwealth Equity Services's LGND Position: Q1 2026 in Review
Commonwealth Equity Services increased its Ligand Pharmaceuticals (LGND) stake by 7.2% in Q1 2026, buying an estimated $15.8K and bringing the position to 1,185 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #3844.
Commonwealth Equity Services first reported a position in LGND in Q3 2014 and has held it in 28 quarters since. The position peaked at $980K in Q4 2021. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Commonwealth Equity Services held 1,185 shares of Ligand Pharmaceuticals worth $237K as of Q1 2026.
- Commonwealth Equity Services bought 80 Ligand Pharmaceuticals shares in Q1 2026, an estimated $15.8K.
- Ligand Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #3844 holding.
- Commonwealth Equity Services first reported a position in Ligand Pharmaceuticals in Q3 2014 and has held it in 28 quarters since.
- Commonwealth Equity Services's Ligand Pharmaceuticals position peaked at $980K in Q4 2021.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.